Invus Group Amends Lexicon Pharma Stake Filing

TL;DR

Invus Group updated their Lexicon Pharma filing on 12/9. Watch for ownership changes.

AI Summary

Invus, L.P. and its affiliates have filed a Schedule 13D/A amendment on December 9, 2024, regarding their holdings in Lexicon Pharmaceuticals, Inc. The filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. The group, which includes entities like ARTAL GROUP S.A. and INVUS ADVISORS, L.L.C., is reporting on their stake in the pharmaceutical company.

Why It Matters

This filing signals a potential shift in the ownership structure or strategy of Lexicon Pharmaceuticals, Inc., which could impact its stock price and future business decisions.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate actions or market movements, warranting close attention.

Key Players & Entities

• Invus, L.P. (company) — Filing entity
• Lexicon Pharmaceuticals, Inc. (company) — Subject company
• ARTAL GROUP S.A. (company) — Group member
• INVUS ADVISORS, L.L.C. (company) — Group member
• MR. AMAURY WITTOUCK (person) — Group member
• MR. RAYMOND DEBBANE (person) — Group member

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d882997dsc13da.htm (SC 13D/A) — 268KB
• d882997dex9929.htm (EX-99.29) — 19KB
• 0001193125-24-273713.txt ( ) — 290KB

of the Statement is hereby amended and restated in its entirety as follows

Item 2 of the Statement is hereby amended and restated in its entirety as follows: This statement is being filed jointly by Invus, L.P., a Bermuda limited partnership, Invus Advisors, L.L.C., a Delaware limited liability company, Invus Public Equities, L.P., a Bermuda limited partnership, Invus Public Equities Advisors, LLC, a Delaware limited liability company, Invus US Partners LLC, a Delaware limited liability company, Invus Global Management, LLC, a Delaware limited liability company, Siren, L.L.C., a Delaware limited liability company, Ulys, L.L.C., a Delaware limited liability company, Mr. Raymond Debbane, a citizen of Panama, Artal Participations S.à r.l., a company incorporated and registered under the laws of Luxembourg, Artal International S.C.A., a Luxembourg limited partnership, Artal International Management S.A., a Luxembourg société anonyme, Artal Group S.A., a Luxembourg société anonyme, Westend S.A., a Luxembourg société anonyme ( Westend ), Stichting Administratiekantoor Westend, a Netherlands foundation (the Stichting ), and Mr. Amaury Wittouck, a citizen of Belgium (collectively, the Reporting Persons ). The address of the principal place of business and principal office of Invus, L.P., Invus Public Equities, L.P., Invus US Partners LLC, Invus Global Management, LLC, Siren, L.L.C., Invus Advisors, L.L.C., Invus Public Equities Advisors, LLC and Ulys, L.L.C. is c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022. The business address for Mr. Debbane is c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022. The address of the principal place of business and principal office of Artal Participations S.à r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend and Mr. Amaury Wittouck is 44, Rue de la Vallée, L-2661, Luxembourg, Luxembourg. The address of the principal place of business and princ

of the Statement is hereby amended and supplemented as follows

Item 4 of the Statement is hereby amended and supplemented as follows: On December 5, 2024, Artal International S.C.A. transferred 136,180,481 shares of Issuer Common Stock to its wholly owned subsidiary, Artal Participations S.à r.l. Item5. Interest in Securities of the Issuer

(a), Item 5(b) and Item 5(c) of the Statement is each hereby amended and restated in its entirety as follows

Item 5(a), Item 5(b) and Item 5(c) of the Statement is each hereby amended and restated in its entirety as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3 and 6 is incorporated by reference in its entirety into this Item 5. (a)-(b) Invus Public Equities, L.P. is the record and beneficial owner of 3,516,214 shares of Issuer Common Stock, representing approximately 1.0% of the outstanding shares of Issuer Common Stock. Invus Public Equities Advisors, LLC, as the general partner of Invus Public Equities, L.P., controls Invus Public Equities, L.P. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock held by Invus Public Equities, L.P. Invus Global Management, LLC, as the managing member of Invus Public Equities Advisors, LLC, controls Invus Public Equities Advisors, LLC and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Invus Public Equities Advisors, LLC may be deemed to beneficially own. Siren, L.L.C., as the managing member of Invus Global Management, LLC, controls Invus Global Management, LLC and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Invus Global Management, LLC may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, L.L.C., controls Siren, L.L.C. and, accordingly, may be deemed to beneficially own the shares of Issuer Common Stock that Siren, L.L.C. may be deemed to beneficially own. Each of Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C. and Mr. Debbane disclaims such beneficial ownership. Invus, L.P. is the record owner of 35,402,689 shares of Issuer Common Stock and the beneficial owner of 38,918,903 shares of Issuer Common Stock, representing approximately 9.8% and approximately 10.8% of the outstanding shares of Issuer Common Stock, respectively.